- Baseline scintigraphic detection of TNFa as a predictor of therapy response after treatment with certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients
- Selecting patients with spondyloarthritis (SpA) or rheumatoid arthritis (RA) for antiTNF-alfa treatment: First scintigraphic data with Tc99m-labelled certolizumab pegol.
- 3 T DCE-MRI assessment of synovitis of the interphalangeal joints in patients with erosive osteoarthritis for treatment response monitoring
- Scintigraphic detection of TNF alpha with a radiolabeled anti-TNF alpha in patients with active peripheral spondyloarthritis and rheumatoid arthritis
99mTc labelled S-HYNIC certolizumab pegol for selecting patients for anti-TNF alpha treatment: a biodistribution and dosimetric study
2013) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 40(suppl. 2). p.S392-S392 Mark(